Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
Parkinsonism Caused by Petroleum Waste Ingestion
Neurol 44:1051-1054, Tetrud,J.W.,et al, 1994
Nigral Dysfunction in Drug-Induced Parkinsonism:An F-dopa PET Study
Neurol 43:552-556, Burn,D.J.&Brooks,D.J., 1993
Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by MPTP
NEJM 327:1556-1563, 15891992., Widner,H.,et al, 1992
Cyanide-Induced Parkinsonism:Clinical, MRI, and 6-Fluorodopa PET Studies
Neurol 39:142-144, Rosenberg,N.L.,et al, 1989
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
HIV-Related Movement Disorders, Epidemiology, Pathogenesis and Management
CNS Drugs 16:663-668, Cardoso,F., 2002
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Reversible Parkinsonism and Cognitive Impairment with Chronic Valproate Use
Neurol 47:626-635, Armon,C.,et al, 1996
Clinical and Pathological Features in Hydrocarbon-Induced Parkinsonism
Ann Neurol 40:922-925, Pezzoli,G.,et al, 1996
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Disabling Parkinsonism Due to Lithium: A Case Report
J Geriatr Psychiatry Neurol 8:118-119, Holroyd,S. & Smith,D., 1995
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Drug-Induced Movement Disorders:An Overview
In Movement Dis in Neurol & Neuropsych, Blackwell Sci Publ, Boston, 2:21., Miller,L.G.&Jankovic,J., 1992
Parkinsonism and Amiodarone Therapy
Ann Neurol 25:630-632, Werner,E.G.&Olanow,C.W., 1989
Mild Parkinsonism in Persons Exposed to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
Neurol 39:1483-1487, Tetrud,J.W.,et al, 1989
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Parkinsonism, Tremor, and Depression Induced by Cinnarizine and Flunarizine
BMJ 297:722-723, Capella,D.,et al, 1988
Extrapyramidal Disturbances Caused by Inappropriate Prescribing
BMJ 295:30-31, Pall,H.S.&Williams,A.C., 1987
Flunarizine- & -Cinnarizine-Induced Extrapyramidal Reactions
Neurol 37:881-884, Micheli,F.,et al, 1987
Parkinsonism, Tardive Dyskinesia, Akathisia, & Depression Induced by Flunarizine
Lancet 1:1303-1304, Chouza,C.,et al, 1986
Drug-Induced Parkinsonism in the Elderly
Lancet 2:1082-1083, Stephen,P.J.,et al, 1984
Parkinson's Disease in a Chemist Working with l-Methyl-4-Phenyl-1, 2, 5, 6-Tetrahydropyridine
NEJM 309:310, Langston,J.W.,et al, 1983
A Danger In Making The Diagnosis Of Parkinson's Disease
Lancet 1:1212-1213, Murdoch,P.S.,et al, 1982
Reversible Drug-Induced Parkinsonism
Arch Neurol 39:644-646, Rajput,A.H.,et al, 1982
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980